Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium

Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium

Enfortumab vedotin (EV) in combination with pembrolizumab (P) has led to a new paradigm for the treatment of metastatic urothelial carcinoma (mUC). Since the presentation of the results of the EV-302 trial at the European Society of Medical Oncology 2023 annual meeting, the entire treatment landscap...

Full description

Saved in:
Bibliographic Details
Main Authors: Catherine C. Fahey, Sean Clark-Garvey, Sima Porten, Ashish M. Kamat, Thomas W. Flaig, John A. Taylor, William Y. Kim, Matthew I. Milowsky
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Current Oncology
Subjects:
urothelial carcinoma
antibody drug conjugate
immunotherapy
enfortumab vedotin
pembrolizumab
biomarkers
Online Access:https://www.mdpi.com/1718-7729/32/5/278
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1718-7729/32/5/278

Similar Items